A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study)-Reference-Cited by-同舟云学术

A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study)

Published:2019-06 Issue:4 Volume:154 Page:
ISSN:0392-0488
Container-title:Giornale Italiano di Dermatologia e Venereologia
language:
Short-container-title:G Ital Dermatol Venereol

Author:

Stinco Giuseppe,Balato Nicola,Buligan Cinzia,Campanati Anna,Dastoli Stefano,Di Meo Nicola,Gisondi Paolo,Lacarubba Francesco,Musumeci Maria L.,Napolitano Maddalena,Offidani Annamaria,Pescitelli Leonardo,Piaserico Stefano,Piccirillo Angelo,Prignano Francesca,Errichetti Enzo

Publisher

Edizioni Minerva Medica

Subject

Dermatology

Link

https://www.minervamedica.it/pdf.php?cod=R23Y2019N04A0392

Reference17 articles.

1. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis];Moreno-Ramírez D;Actas Dermosifiliogr,2011

2. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study

3. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

4. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

5. Disease Control for Patients with Psoriasis Receiving Continuous Versus Interrupted Therapy with Adalimumab or Etanercept: A Clinical Practice Study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation;Immunity;2024-07

2. Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis;Biomolecules;2024-05-03

3. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era;Rheumatology International;2022-05-03

4. Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study;Acta Dermato Venereologica;2021

5. Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial;Journal of the European Academy of Dermatology and Venereology;2020-11-05